- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Crizotinib, as an ALK/ROS1 inhibitor, has been launched in China. However, attention should be paid to the approval status and medication safet...
Crizotinib has been approved for marketing in China and is mainly used for the treatment of ALK positive non-small cell lung cancer. Patients n...
Crizotinib has significant therapeutic effects on ALK positive non-small cell lung cancer, with an objective remission rate of 60% -80%. It can...
The standard dose of Crizotinib is 250mg orally twice daily and should be taken with meals to increase bioavailability. For special populations...
Eltrombopag is an oral thrombopoietin receptor agonist primarily used to treat thrombocytopenia by stimulating megakaryocyte proliferation and ...
Eltrombopag is an oral thrombopoietin receptor agonist primarily used to treat specific types of thrombocytopenia, including chronic liver di...
Eltrombopag is an oral thrombopoietin receptor agonist primarily used to treat specific types of thrombocytopenia, including chronic liver di...
Eltrombopag is an oral thrombopoietin receptor agonist primarily used to treat chronic liver disease-related thrombocytopenia and chronic immun...
Eltrombopag, as a thrombopoietin receptor agonist, is suitable for the treatment of chronic liver disease-related thrombocytopenia and chronic ...
The correct use of eltrombopag requires strict adherence to indications and individualized dosage requirements. Key points include co administr...
